Kadance
Kadance is a US-based precision health management company offering hereditary cancer risk testing, pharmacogenomics, genetic counseling, and oncology nurse navigation, delivered via insurance-carrier partnerships (Chubb, Nationwide) and direct-to-consumer membership.
- Company typePrivate
- Founded2019
- HeadquartersHuntsville, United States
- Headcount11–50
- GTM typeB2B and B2C
- OfferingSoftware
What Kadance does
Kadance (formerly healthōme, Inc.) is a US-based precision health management company founded in 2019 and headquartered at the HudsonAlpha Institute for Biotechnology in Huntsville, Alabama. Its core offering combines hereditary cancer risk testing (a 26+ gene panel covering BRCA1/2, Lynch syndrome, PALB2 and other clinically actionable genes), pharmacogenomic testing (drug response profiling), genetic counseling, oncology nurse navigation, molecular pathologist consultations, blood-based cancer recurrence monitoring (ctDNA/liquid biopsy), and clinical trial enrollment support into a single membership-based platform. Testing is performed through CAP-accredited, CLIA-certified laboratory partners, including its wholly-owned subsidiary Kailos Genetics and partner lab Protean Biodiagnostics, with care delivery supported by SteadyMD (provider/counselor layer) and GalenusRx (clinical pharmacist consultations).
The commercial model is hybrid. The primary channel is B2B2C enterprise partnerships with life and workplace insurance carriers — notably Chubb Workplace Benefits (Cancer Advocate Plus, launched 2023) and Nationwide (Precision Health Management Program, 2025) — which embed Kadance's services as a policyholder benefit at no incremental cost to the member. A parallel direct-to-consumer channel operates through the Kadance website and member portal (myhealth.kadance.com), offering subscription-based membership tiers named Complete, Navigate, and Recover that target prevention, active cancer patients, and post-treatment survivors, respectively. Pricing is described as subscription/recurring, with insurance coverage or membership fees absorbing service costs and future add-ons contemplated by the Terms of Service.
Kadance monetizes through recurring membership fees and carrier enterprise agreements. Strategic capital partners include American Family Ventures and AllegisNL Capital (seed, 2023) and Nassau Financial Group via the Nassau Reimagine program (2026). The company reports 11–50 employees and is privately held as a Delaware corporation, having been rebranded from healthōme to Kadance in 2023/2024 to align its identity with insurance-channel distribution. Leadership includes Darren Rowe (CEO), David Stertzer (Co-Founder), Terri Kinloch (CXO), Louis Davis (CTO), Kimberly Scott (Chief Commercial Officer), and Chairperson Anne Melissa Dowling, the latter appointed specifically to deepen carrier-side credibility.
Kadance firmographics
Firmographics- Name
- Kadance
- Legal name
- Kadance, Inc.
- Website
- https://kadance.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Kadance is a US-based precision health management company offering hereditary cancer risk testing, pharmacogenomics, genetic counseling, and oncology nurse navigation, delivered via insurance-carrier partnerships (Chubb, Nationwide) and direct-to-consumer membership.
- Ownership category
- akta.pro rank
Kadance industry classification
Industry- Product category
- Precision Health Management
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)
- akta.pro primary industry
- Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD)
- akta.pro secondary industries
- Molecular Diagnostics (PCR/qPCR, NGS-based assays) (HLAAALAA), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Molecular Tumor Boards & Clinical Interpretation Services (HLAAANAD), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF)
Keywords
Where Kadance is headquartered
LocationHeadquarters
- HQ city
- Huntsville
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Kadance business model
Business model- GTM type
- B2B and B2C
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Precision Health Membership Programs: Kadance offers membership-based programs (Complete, Navigate, Recover) that provide access to hereditary cancer risk testing, genetic counseling, and precision health support. Costs for services are covered by membership, insurance policy, or rider to insurance policy, with no additional charges to members for covered services.
- B2B2C Enterprise Partnerships with Insurance Carriers: Kadance partners with insurance carriers (e.g., Nationwide, Chubb) who embed Kadance's precision health program as a benefit for their policyholders. Kadance receives compensation through these enterprise agreements, and policyholders access services at no additional cost through their insurance benefit.
- Future Add-on Services: The Terms of Service indicate that Kadance may offer add-on or additional products and services for which it may charge fees in the future, payable via credit card with applicable taxes and shipping charges.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Monthly | Kadance Complete Membership |
| Subscription | Monthly | Kadance Navigate Membership |
| Subscription | Monthly | Kadance Recover Membership |
| Subscription | Annual | Insurance-Covered Services |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels7 records
Kadance product offering
Product offeringCore offering
Kadance operates a genomics-based precision health management platform that delivers hereditary cancer risk testing across 26+ clinically actionable genes, pharmacogenomic (PGx) testing, genetic counseling, oncology nurse navigation, molecular pathologist consultations, and blood-based ctDNA cancer recurrence monitoring. Services are sold as recurring memberships (Complete, Navigate, Recover tiers) directly to consumers and bundled as policyholder benefits through partnerships with major U.S. insurance carriers such as Nationwide and Chubb.
Differentiator
Problem solved
Functional benefit
Products and services
- Kadance Complete Membership Subscription membership for prevention-focused individuals delivering hereditary cancer risk testing across 26+ genes, genetic counseling for positive results, prevention planning, and access to coordinated cancer support if cancer is ever diagnosed. No physician referral required; costs covered by membership or insurance policy/rider.
- Kadance Navigate Membership Subscription membership for individuals recently diagnosed with cancer or currently in treatment, providing more targeted precision health support for active cancer patients.
- Kadance Recover Membership Subscription membership for cancer survivors focused on blood-based ctDNA cancer recurrence monitoring and long-term survivorship care support.
- Kadance Precision Health Management Program (Nationwide) Genomics-based health management program embedded as a benefit for eligible Nationwide life insurance policyholders, providing access to DNA testing, pharmacogenomic testing, hereditary cancer risk assessment, and oncology navigation services to support members' health beyond traditional insurance coverage.
- Cancer Advocate Plus (Chubb Workplace Benefits) Genetics-based cancer support program offering cancer screening/risk testing, cancer management support including molecular diagnostic tumor testing and oncology nurse advocacy, cancer recovery monitoring, and insurance benefits, distributed as a voluntary benefit to employees of middle-market and large companies through Chubb Workplace Benefits.
- Genomics-based Personalized Medication Safety Program Personalized medication safety program combining pharmacogenomic testing with personalized medication guidance and clinical pharmacist consultations through partner GalenusRx to reduce adverse drug events.
Quantifiable outcome
- Stage 1 localized cancer detection is associated with approximately 91.1% five-year survival rate vs. approximately 30.6% when cancer has spread
- +6 more outcomes
Companies that use Kadance
Customer profileNamed customers2 records
Segments4 records
Ideal customer profiles3 records
Kadance technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Kadance partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core.
- NationwidecoreNationwide partnered with Kadance to offer a genomics-based health management program for eligible life insurance customers. The program provides access to advanced DNA testing, pharmacogenomic testing, hereditary cancer risk assessment, and oncology navigation services, supporting members' health beyond traditional insurance coverage.
- Chubb Workplace BenefitscoreChubb Workplace Benefits launched Cancer Advocate Plus, a first-of-its-kind genetics-based cancer support program through an exclusive agreement with Kadance (then healthŌme). The program provides policyholders with genetics-based cancer risk testing, pharmacogenomic testing, cancer management support including molecular diagnostic tumor testing and oncology nurse advocacy, cancer recovery monitoring, and insurance benefits — distributed to employees of middle-market and large companies as a voluntary benefit.
- healthŌme and GalenusRxcorehealthŌme (now Kadance) and GalenusRx forged a strategic partnership to launch a genomics-based personalized medication safety program combining pharmacogenomic testing with personalized medication guidance. GalenusRx is one of the Practices referenced in Kadance's Terms of Service that provides clinical pharmacist consultations.
- Kailos Genetics, LLCcoreKailos Genetics, LLC is a wholly owned subsidiary of Kadance, Inc. It serves as one of Kadance's clinical laboratory partners providing genetic testing services. The acquisition of Kailos Genetics strengthened Kadance's integrated precision health management capabilities. Kailos Genetics is a CAP-accredited, CLIA-certified laboratory.
- SteadyMDcoreSteadyMD is one of the licensed medical practices that provides professional genetic testing ordering, interpretation, genetic counseling, and telemedicine services to Kadance members. Kadance facilitates access to SteadyMD's licensed healthcare providers and genetic counselors through its platform.
- Protean BiodiagnosticscoreProtean Biodiagnostics is one of the clinical laboratories and licensed medical practices providing genetic testing, molecular pathologist consultations, and healthcare provider services to Kadance members. It is a CAP-accredited, CLIA-certified laboratory referenced in Kadance's Terms of Service and blog content.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
Kadance competitors and assessment
Company assessmentDirect peers
- Genomic Life: Genomic Life offers genetic testing and precision health programs integrated into insurance products, including employer-sponsored plans. Highly comparable to Kadance's insurtech-genomics business model of embedding testing within carrier benefits.
- Natera: Natera is a clinical-grade genetic testing company offering hereditary cancer panels, pharmacogenomics, and liquid biopsy recurrence monitoring. Overlaps with Kadance on hereditary cancer testing and ctDNA recurrence monitoring, though Natera operates more on a clinical/provider channel model.
- Color Genomics: Color is a population genomics company offering hereditary cancer and pharmacogenomic testing to individuals, employers, and health plans. Directly comparable to Kadance in panel scope, clinical-grade lab operations, and B2B2C distribution model targeting large employer and health plan customers.
Broad incumbents
- Quest Diagnostics: Quest Diagnostics is one of the largest clinical laboratory networks offering hereditary cancer and pharmacogenomic testing. As a broad incumbent, Quest has the scale and payor relationships Kadance lacks, though its offering is not consumer-direct or insurance-embedded.
- 23andMe: 23andMe is the largest consumer-facing genetic testing brand, offering hereditary cancer risk reports and pharmacogenomic insights. Competes with Kadance on consumer awareness and direct-to-consumer accessibility, though its tests are not clinical-grade or insurance-embedded.
- Labcorp: Labcorp is a major clinical laboratory operator offering hereditary cancer panels and now Invitae-powered genetic testing. As a broad incumbent, Labcorp has payor relationships and clinical lab scale that Kadance lacks; competitive threat exists if Labcorp pursues insurance-embedded offerings similar to Kadance's model.
- Myriad Genetics: Myriad is an established molecular diagnostics company with deep hereditary cancer testing heritage (BRACAnalysis, myRisk). Comparable on hereditary cancer panel offerings and clinical lab operations, though Myriad serves primarily provider channels rather than insurance-embedded benefits.
Emerging players
- GalenusRx: GalenusRx is a pharmacogenomics clinical services firm that is also a strategic partner of Kadance (provides pharmacist consultations). Comparable on PGx clinical service delivery and medication safety programs targeted at insurance/payer customers.
- Invitae: Invitae (now part of Labcorp) offers comprehensive genetic testing including hereditary cancer panels with a focus on accessibility. Comparable on panel breadth and clinical-grade lab operations; however, it has been navigating financial distress which may affect competitive positioning.
- GenXys: GenXys is a pharmacogenomics-focused company offering medication safety software and PGx testing. Co-featured alongside Kadance in an Inside Precision Medicine article on pharmacogenomics startups; comparable on the PGx/medication-safety use case embedded into insurance products.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Kadance social profiles
Digital presenceKadance financial estimates
Financial estimateRevenue estimate
Valuation estimate
Kadance leadership team
Management profileNumber of profiles
Profiles6 records
Kadance subsidiaries and ownership
Company hierarchySubsidiaries1 record
Kadance funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Kadance M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Kadance
What does Kadance do?
Kadance operates a genomics-based precision health management platform that delivers hereditary cancer risk testing across 26+ clinically actionable genes, pharmacogenomic (PGx) testing, genetic counseling, oncology nurse navigation, molecular pathologist consultations, and blood-based ctDNA cancer recurrence monitoring. Services are sold as recurring memberships (Complete, Navigate, Recover tiers) directly to consumers and bundled as policyholder benefits through partnerships with major U.S. insurance carriers such as Nationwide and Chubb.
Is Kadance a public or private company?
Kadance is a private company. It is classified as venture growth investor backed and is currently operating.
When was Kadance founded?
Kadance was founded in 2019. It employs 11 to 50 people.
Where is Kadance based?
Kadance is headquartered in Huntsville, United States, in the North America region.
How does Kadance make money?
Three revenue lines are on record. Precision Health Membership Programs are the primary driver. The others are B2B2C Enterprise Partnerships with Insurance Carriers and future Add-on Services.
Who are Kadance's main competitors?
Direct peers on record are Genomic Life, Natera and Color Genomics. Broad incumbents are Quest Diagnostics, 23andMe, Labcorp and Myriad Genetics. Emerging players are GalenusRx, Invitae and GenXys.
Does Kadance have an API?
No public API is recorded for Kadance.
What industry is Kadance in?
Kadance's product category is Precision Health Management. Its primary akta.pro industry code is HLAAALAD, Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics), with a secondary code of HLAAALAA, Molecular Diagnostics (PCR/qPCR, NGS-based assays). Its NAICS code is 541714 and its SIC code is 2835.